DE244380T1 - Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung. - Google Patents
Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung.Info
- Publication number
- DE244380T1 DE244380T1 DE198787850126T DE87850126T DE244380T1 DE 244380 T1 DE244380 T1 DE 244380T1 DE 198787850126 T DE198787850126 T DE 198787850126T DE 87850126 T DE87850126 T DE 87850126T DE 244380 T1 DE244380 T1 DE 244380T1
- Authority
- DE
- Germany
- Prior art keywords
- alkaline
- compound
- labile compound
- compounds
- acidic labile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 41
- 230000002378 acidificating effect Effects 0.000 claims 18
- 239000011162 core material Substances 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 10
- 239000010410 layer Substances 0.000 claims 9
- 159000000011 group IA salts Chemical class 0.000 claims 7
- 239000000395 magnesium oxide Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- 239000002131 composite material Substances 0.000 claims 4
- 230000000968 intestinal effect Effects 0.000 claims 4
- 239000000347 magnesium hydroxide Substances 0.000 claims 4
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 239000011247 coating layer Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- -1 compounds magnesium oxide Chemical class 0.000 claims 3
- 239000011777 magnesium Substances 0.000 claims 3
- 229910052749 magnesium Inorganic materials 0.000 claims 3
- JVIHSTYYPRUSFG-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 JVIHSTYYPRUSFG-UHFFFAOYSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- PPQREHKVAOVYBT-UHFFFAOYSA-H aluminium carbonate Inorganic materials [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 2
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000003139 buffering effect Effects 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 239000001095 magnesium carbonate Substances 0.000 claims 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 2
- 229960000381 omeprazole Drugs 0.000 claims 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- 239000006174 pH buffer Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 239000011591 potassium Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 2
- 235000011082 potassium citrates Nutrition 0.000 claims 2
- 235000011009 potassium phosphates Nutrition 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- HAEAHRRWDSAOPD-UHFFFAOYSA-N 5-methoxy-1-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazole Chemical compound C1=NC2=CC(OC)=CC=C2N1S(=O)CC1=NC=C(C)C(OC)=C1C HAEAHRRWDSAOPD-UHFFFAOYSA-N 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (1)
- 87 850 126.1 - 0 244 380
Aktiebolaget HässlePatentansprücheOrales pharmazeutisches Präparat mit einem Gehalt an saurer labiler Verbindung als aktiver Bestandteil, dadurch gekennzeichnet, daß es aus Kernmaterial, das den aktiven Bestandteil zusammen mit einer alkalisch reagierenden Verbindung oder ein alkalisches Salz des aktiven Bestandteils gegebenenfalls zusammen mit einer alkalisch reagierenden Verbindung enthält, und auf dem Kernmaterial eine oder mehrere inert reagierende Unterzugschichten, welche Tablettenbindemittel, die in Wasser löslich sind oder schnell zergehen, oder polymere wasserlösliche filmbildende Verbindungen umfassen und gegebenenfalls pH-Puffer und alkalische Verbindungen enthalten, zwischen dem alkalisch reagierenden Kern und einer Außenschicht, die ein Darmüberzug ist, aufgebaut ist.Präparat nach Anspruch 1, worin die saure labile Verbindung die allgemeine Formel I hatworin A eine gegebenenfalls substituierte heterozyklischeGruppe ist, R'und R gleich oder verschiedensind und vorzugsweise niedermolekulares Alkyl, niedermo-lekulares Alkoxy, -CF.,, -O-C-Niederalkyl oder Halogen sindund R H oder eine niedermolekulare Alkylgruppe ist, worin "niedermolekular" 1 bis 6 Kohlenstoffatome bedeutet,ausgenommen die Verbindung Omeprazol, 5-Methoxy-[ [ ( 4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]-sulfinyl]-lH-benzimidazol oder daß die saure labile Verbindung 2-[(2-Dimethylaminobenzyl)-sulfinyl]-benzimidazol ist.3. Präparat nach Anspruch 1, worin die Unterzugschicht eine oder mehrere der Verbindungen Magnesiumoxid, Magnesiumhydroxid oder der zusammengesetzten Substanz (Al3O3 . 6MgO . 12H2O oder MgCAl3O3 . 2SiO2 . nH20) umfaßt, worin &eegr; nicht eine ganze Zahl und geringer als 2 ist.4. Präparat nach Anspruch 2 oder 3, worin der Unterzug zwei oder mehr Unterschichten umfaßt.5. Präparat nach Anspruch 4, worin der Unterzug Hydroxypropylmethylcellulose., Hydroxypropylcellulose oder Polyvinylpyrrolidon ist.6. Präparat nach Anspruch 1, worin der alkalische Kern die saure labile Verbindung und die pH-puffernde alkalische Verbindung umfaßt, die die Mikroumgebung der sauren labilen Verbindung auf pH 7 bis 12 bringt.7. Präparat nach Anspruch 6, worin die alkalische Verbindung eine oder mehrere der Verbindungen Magnesiumoxid, -hydroxid oder -carbonat, Aluminiumhydroxid, Aluminium-, Calcium-, Natrium- oder Kaliumcarbonat, -phosphat oder -citrat oder die zusammengesetzten Aluminium/Magnesium-Verbindungen Al2 . 6MgO . CO2 . 12H2O oder MgO . Al3O3 . 2SiO2 . nH~0 umfaßt, worin &eegr; nicht eine ganze Zahl und weniger als 2 ist.8. Präparat nach Anspruch 1, worin der alkalische Kern ein alkalisches Salz der sauren labilen Verbindung, wie das 5 Natrium-, Kalium-, Magnesium-, Calcium- oder Ammoniumsalz umfaßt.9. Präparat nach Anspruch 7, worin der alkalische Kern einalkalisches Salz der sauren labilen Verbindung, gemischt mit einer inerten alkalischen Verbindung umfaßt.10. Präparat nach Anspruch 1, worin der Darmüberzug Hydroxypropylmethylcellulosephthalat, Celluloseacetatphthalat, copolymerisierten Methacrylsäure/Methacrylsäuremethylester oder Polyvinylacetatphthalat, gegebenenfalls mit einem Gehalt eines Weichmachers, umfaßt.11. Präparat nach Anspruch 1, worin der Wassergehalt der fertigen Dosierungsform, die die saure labile Verbindung enthält, 1,5 Gew.-% nicht übersteigt.12. Verfahren zur Herstellung einer oralen pharmazeutischen Formulierung, die eine saure labile Verbindung enthält, bei dem man Kerne, die die saure labile Verbindung im Gemisch mit einer alkalisch reagierenden Verbindung oder solchen Verbindungen oder ein alkalisches Salz der sauren labilen Verbindung, gegebenenfalls im Gemisch mit einer alkalisch reagierenden Verbindung oder solchen Verbindungen enthalten, mit einer oder mehreren inert reagierenden Unterzugschicht(en) überzieht, wonach die mit Unterzug versehenen Kerne weiterhin mit einer Darmüberzugsschicht überzogen werden.13. Verwendung des Präparates nach Anspruch 1 zur Herstellung eines Arzneimittels zur Behandlung von Magen-Darm-Erkrankungen .Aktiebolaget HassePatentansprüche (für die Vertragsstaaten AT, ES, GR)
1. Verfahren zur Herstellung einer oralen pharmazeutischen Formulierung, die als den aktiven Bestandteil eine saure labile Verbindung enthält, dadurch gekennzeichnet, daß man die Kerne, die die saure labile Verbindung im Gemisch mit einer alkalisch reagierenden Verbindung oder ein alkalisches Salz des aktiven Bestandteils gegebenenfalls zusammen mit einer alkalisch reagierenden Verbindung enthalten, mit einer oder mehreren inert reagierenden Unterzugschichten, die Tablettenbindemittel, die in Wasser löslich sind oder leicht zergehen, oder polymere, wasserlösliche filmbildende Verbindungen umfassen und gegebenenfalls pH-Puffer und alkalische Verbindungen enthalten, zwischen dem alkalisch reagierenden Kern und einer Außenschicht, die eine Darmüberzugsschicht ist, überzieht, wonach die mit Unterzug versehenen Kerne weiterhin mit der äußeren Darmüberzugsschicht überzogen werden.2. Verfahren nach Anspruch 1, worin die saure labile Verbindung die allgemeine Formel Ihat, worin A eine gegebenenfalls substituierte heterozyk-12 3 4lische Gruppe ist, R , R , R und R gleich oder verschieden sind und vorzugsweise Wasserstoff, niedermoleku-11lares Alkyl, niedermolekulares Alkoxy, -CF.,, -O-C-Niederalkyl oder Halogen sind und R H oder eine niedermolekulare Alkylgruppe ist, worin "niedermolekular" 1 bis 6 Kohlenstoffatome bedeutet, mit Ausnahme der Verbindung Omeprazol, 5-Methoxy-2- [[(4-methoxy-3,5-dimethyl-2-pyri-dinyl)-methyl ]-sulfinyl ]-lH-benzimidazol oder daß die saure labile Verbindung 2-[(2-Dimethylaminobenzyl)-sulfinyl ]-benzimidazol ist.3. Verfahren nach Anspruch 1, worin die Unterzugschicht eine oder mehrere der Verbindungen Magnesiumoxid, Magnesiumhydroxid oder der zusammengesetzten Substanz (Al-O^ . 6MgO . CO2 . 12H2O oder MgO . Al3O3 . 2SiO2 . nH20) umfaßt, worin &eegr; nicht eine ganze Zahl und weniger als 2 ist.4. Verfahren nach Anspruch 2 oder 3, worin der Unterzug zwei oder mehr Unterschichten umfaßt.5. Verfahren nach Anspruch 4, worin der Unterzug Hydroxypropylmethylcellulose, Hydroxypropylcellulose oder Polyvinylpyrrolidon umfaßt.6. Verfahren nach Anspruch 1, worin der alkalische Kern die saure labile Verbindung und pH-puffernde alkalische Verbindung, die die Mikroumgebung der sauren labilen Verbindung auf pH 7 bis 12 bringt, umfaßt.7. Verfahren nach Anspruch 6, worin die alkalische Verbindung eine oder mehrere der Verbindungen Magnesiumoxid, -hydroxid oder -carbonat, Aluminiumhydroxid, Aluminium-, Calcium-, Natrium- oder Kaliumcarbonat, -phosphat oder -citrat oder der zusammengesetzten Aluminium/Magnesium-2
Verbindungen Al O3. 6MgO . CO3 . 12H3O oder MgO . Al3O3 .2SiO- . nH„0, worin &eegr; nicht eine ganze Zahl und weniger als 2 ist, umfaßt.8. Verfahren nach Anspruch 1, worin der alkalische Kern ein alkalisches Salz der sauren labilen Verbindung, wie das Natrium-, Kalium-, Magnesium-, Calcium- oder Ammoniumsalz umfaßt.9. Verfahren nach Anspruch 7, worin der alkalische Kern ein alkalisches Salz der sauren labilen Verbindung im Gemisch mit einer inerten alkalischen Verbindung umfaßt.10. Verfahren nach Anspruch 1, worin der Darmüberzug Hydroxypropylmethylcellulosephthalat, CeIluloseacetatphthalat, copolymerisierten Methacrylsäure/Methacrylsäuremethylester oder Polyvinylacetatphthalat, gegebenenfalls mit einem Gehalt an Weichmacher, umfaßt.11. Verfahren nach Anspruch 1, worin der Wassergehalt der02443301 fertigen Dosierungsform, die die saure labile Verbindungenthält, 1,5 Gew.-% nicht übersteigt.12. Verwendung der nach Anspruch 1 hergestellten Formulierung zur Herstellung eines Arzneimittels für die Behand-5 lung von Magen-Darm-Erkrankungen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08610573A GB2189699A (en) | 1986-04-30 | 1986-04-30 | Coated acid-labile medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
DE244380T1 true DE244380T1 (de) | 1990-02-08 |
Family
ID=10597119
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3751851T Expired - Lifetime DE3751851T2 (de) | 1986-04-30 | 1987-04-16 | Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung säurelabiler Verbindungen sind |
DE198787850126T Pending DE244380T1 (de) | 1986-04-30 | 1987-04-16 | Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung. |
DE8787850126T Expired - Lifetime DE3783386T2 (de) | 1986-04-30 | 1987-04-16 | Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3751851T Expired - Lifetime DE3751851T2 (de) | 1986-04-30 | 1987-04-16 | Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung säurelabiler Verbindungen sind |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8787850126T Expired - Lifetime DE3783386T2 (de) | 1986-04-30 | 1987-04-16 | Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung. |
Country Status (33)
Country | Link |
---|---|
US (1) | US4853230A (de) |
EP (3) | EP0565210B1 (de) |
JP (1) | JPH0667837B2 (de) |
KR (1) | KR950004886B1 (de) |
CN (1) | CN1025151C (de) |
AR (1) | AR243377A1 (de) |
AT (2) | ATE186639T1 (de) |
AU (1) | AU603568B2 (de) |
CA (1) | CA1302891C (de) |
CS (1) | CS268535B2 (de) |
CY (1) | CY1860A (de) |
DD (1) | DD260222B5 (de) |
DE (3) | DE3751851T2 (de) |
DK (1) | DK169987B1 (de) |
DZ (1) | DZ1078A1 (de) |
EG (1) | EG18517A (de) |
ES (2) | ES2010648T3 (de) |
FI (1) | FI91708C (de) |
GB (1) | GB2189699A (de) |
GR (2) | GR890300156T1 (de) |
HK (2) | HK104095A (de) |
HU (1) | HU198385B (de) |
IE (1) | IE61837B1 (de) |
IS (1) | IS1918B (de) |
MY (1) | MY102675A (de) |
NO (1) | NO174952C (de) |
NZ (1) | NZ220097A (de) |
PH (1) | PH24440A (de) |
PL (1) | PL265417A1 (de) |
PT (1) | PT84786B (de) |
SU (1) | SU1709894A3 (de) |
YU (1) | YU46421B (de) |
ZA (1) | ZA872379B (de) |
Families Citing this family (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749864B2 (en) * | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US5030447A (en) * | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
EP0425699B1 (de) * | 1989-05-11 | 1994-08-17 | Chugai Seiyaku Kabushiki Kaisha | Mundzubereitung zur verabreichung an bestimmter stelle des darmes |
GR1002098B (en) * | 1989-06-08 | 1995-12-28 | Squibb & Sons Inc | Pharmaceutical composition having good stability |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
PH27186A (en) * | 1989-09-07 | 1993-04-16 | Ciba Geigy Ag | Double-coated granules of disodium pamidronate |
KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
IT1245890B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
IT1245891B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
US6764697B1 (en) * | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
ZA937382B (en) * | 1992-10-06 | 1994-04-29 | Warner Lambert Co | Novel composition for peroral therapy of cognitionimpairment and a process therefor |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
TW280770B (de) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
UA41946C2 (uk) * | 1994-07-08 | 2001-10-15 | Астра Актієболаг | Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань |
US5508276A (en) * | 1994-07-18 | 1996-04-16 | Eli Lilly And Company | Duloxetine enteric pellets |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
PL186605B1 (pl) * | 1995-09-21 | 2004-01-30 | Pharma Pass Llc | Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
SE512835C2 (sv) * | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
SE9602442D0 (sv) * | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US5910319A (en) | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
SI9700186B (sl) | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
WO1999027917A1 (de) * | 1997-11-28 | 1999-06-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Arzneimittelzubereitung in tabletten- oder pelletform für säurelabile wirkstoffe |
DE19752843C2 (de) * | 1997-11-28 | 2003-01-09 | Byk Gulden Lomberg Chem Fab | Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
JP4127740B2 (ja) * | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
ES2559766T3 (es) | 1998-05-18 | 2016-02-15 | Takeda Pharmaceutical Company Limited | Comprimidos disgregables en la boca |
UA69413C2 (uk) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
SI1105105T1 (sl) | 1998-08-12 | 2006-08-31 | Altana Pharma Ag | Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole |
US6733778B1 (en) | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
AU1316200A (en) | 1998-10-15 | 2000-05-01 | Chiron Corporation | Metastatic breast and colon cancer regulated genes |
WO2000026185A2 (en) * | 1998-10-30 | 2000-05-11 | The Curators Of The University Of Missouri | Omeprazole solution and method of using same |
TWI242000B (en) | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
PT1141331E (pt) | 1998-12-16 | 2008-12-22 | Novartis Vaccines & Diagnostic | Quinase dependente de ciclina humana (hpnqalre) |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
US6210716B1 (en) * | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6197329B1 (en) | 1999-05-03 | 2001-03-06 | Drugtech Corporation | Anti-nausea compositions and methods |
ATE300285T1 (de) | 1999-06-07 | 2005-08-15 | Altana Pharma Ag | Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor |
IL130602A0 (en) * | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
KR20020038759A (ko) | 1999-10-20 | 2002-05-23 | 다니구치 미즈오 | 벤즈이미다졸계 화합물 안정화 방법 |
DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
US7732404B2 (en) | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
ES2311016T3 (es) | 2000-01-10 | 2009-02-01 | Novartis Vaccines And Diagnostics, Inc. | Genes expresados diferencialmente en cancer de mama. |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US6306435B1 (en) | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
US6749867B2 (en) | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
CA2430816C (en) | 2000-12-07 | 2012-05-15 | Altana Pharma Ag | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
JP2004514737A (ja) | 2000-12-07 | 2004-05-20 | アルタナ ファルマ アクチエンゲゼルシャフト | 酸分解性活性成分を含有する迅速に崩壊する錠剤 |
WO2002045692A1 (en) | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
JP5005157B2 (ja) * | 2001-03-13 | 2012-08-22 | ペンウェスト ファーマシューティカルズ カンパニー | 時間治療(chronotherapeutic)投与形態 |
US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
US7309783B2 (en) * | 2001-05-09 | 2007-12-18 | The University Of Connecticut | Mammalian early developmental regulator gene |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US6543389B2 (en) | 2001-06-26 | 2003-04-08 | Pfizer Inc. | Insecticidal pet collar |
BR0212950A (pt) * | 2001-09-28 | 2004-10-26 | Mcneil Ppc Inc | Formas de dosagens compósitas tendo uma porção inserida |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
WO2003032953A1 (fr) * | 2001-10-17 | 2003-04-24 | Takeda Chemical Industries, Ltd. | Granules contenant un agent chimique instable en milieu acide, en concentration elevee |
ES2198195B1 (es) | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido. |
MXPA04007169A (es) * | 2002-01-25 | 2004-10-29 | Santarus Inc | Suministro transmucosal de inhibidores de bomba de protones. |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
AU2003250468A1 (en) * | 2002-08-16 | 2004-03-03 | Themis Laboratories Private Limited | A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles |
US20050191353A1 (en) * | 2002-08-16 | 2005-09-01 | Amit Krishna Antarkar | Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles |
US7135324B2 (en) * | 2002-09-04 | 2006-11-14 | The University Of Connecticut | Viral recombinases, related articles, and methods of use thereof |
JP4169329B2 (ja) * | 2002-10-04 | 2008-10-22 | 村樫石灰工業株式会社 | 消石灰系塗材組成物 |
EP1552833B1 (de) | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Herstellung eines amorphen, optisch aktiven Isomers von Lansoprazol |
US20040162263A1 (en) * | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
US6893660B2 (en) * | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
WO2004066924A2 (en) * | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
US20040146558A1 (en) * | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
CA2515130A1 (en) | 2003-02-05 | 2004-08-26 | Teva Pharmaceutical Industries Ltd. | Method of stabilizing lansoprazole |
TWI367759B (en) * | 2003-02-20 | 2012-07-11 | Santarus Inc | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid |
US20050031696A1 (en) * | 2003-04-22 | 2005-02-10 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations of acid-labile active ingredients and process for making same |
ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050053669A1 (en) * | 2003-09-05 | 2005-03-10 | Boehringer Ingelheim International Gmbh | Administration form for the oral application of poorly soluble acidic and amphorteric drugs |
DE10341414A1 (de) * | 2003-09-05 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe |
WO2005027878A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Delayed released dosage forms |
MXPA06003101A (es) * | 2003-09-19 | 2006-06-20 | Penwest Pharmaceuticals Co | Formas de dosis cronoterapeuticas. |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
WO2005046634A2 (de) * | 2003-11-14 | 2005-05-26 | Siegfried Generics International Ag | Magensaftresistente verabreichungsform |
HU227317B1 (en) * | 2003-11-25 | 2011-03-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Enteric coated tablet containing pantoprazole |
CN1321642C (zh) * | 2003-12-12 | 2007-06-20 | 南京长澳医药科技有限公司 | 泮托拉唑钠肠溶微丸 |
US20070141150A1 (en) * | 2003-12-30 | 2007-06-21 | Raghupathi Kandarapu | Pharmaceutical composition |
WO2005092297A2 (en) * | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
JP4792390B2 (ja) | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | 新規ガレクチン9改変体タンパク質及びその用途 |
US7491263B2 (en) | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
CA2565083C (en) | 2004-05-07 | 2014-07-08 | Altana Pharma Ag | Novel pharmaceutical dosage form and manufacturing process |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN101111233A (zh) | 2004-12-23 | 2008-01-23 | 兰贝克赛实验室有限公司 | 稳定的口服苯并咪唑组合物及其制备方法 |
WO2006085335A2 (en) * | 2005-01-03 | 2006-08-17 | Lupin Limited | Pharmaceutical composition of acid labile substances |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
EP1845982A2 (de) * | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Durch ein nichtwässriges schichtungsverfahren hergestellte stabile orale benzimidaziol-zusammensetzungen |
KR100570446B1 (ko) * | 2005-02-14 | 2006-04-12 | 지엘팜텍 주식회사 | 산 불안정성 약리활성물질 함유 장용성 경구용 제제 및 이의 제조방법 |
US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
WO2006111853A2 (en) * | 2005-04-18 | 2006-10-26 | Aurobindo Pharma Limited | Stable solid dosage forms of acid labile drug |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
CN101208090B (zh) * | 2005-04-28 | 2012-03-21 | 卫材R&D管理有限公司 | 稳定化的组合物 |
US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
EP1747776A1 (de) * | 2005-07-29 | 2007-01-31 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zubereitung mit granulatförmigem Pantoprazol |
KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
CA2634232C (en) | 2005-12-28 | 2013-08-20 | Takeda Pharmaceutical Company Limited | Method of producing solid preparation disintegrating in the oral cavity |
US8865212B2 (en) * | 2006-01-16 | 2014-10-21 | Jubilant Generics Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
US7579476B2 (en) * | 2006-02-24 | 2009-08-25 | Praktikatalyst Pharma, Llc | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals |
WO2007112581A1 (en) | 2006-04-03 | 2007-10-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
EP2026768B1 (de) * | 2006-06-01 | 2018-02-28 | Dexcel Pharma Technologies Ltd. | Pharmazeutische formulierung auf mehreren einheiten |
EP1872778A1 (de) * | 2006-06-29 | 2008-01-02 | LEK Pharmaceuticals D.D. | Stabile pharmazeutische Formulierung enthaltend Rabeprazol-Natrium |
EP2046334B1 (de) | 2006-07-25 | 2014-05-21 | Vecta Ltd. | Zusammensetzungen und verfahren zur hemmung von magensäuresekretion anhand von derivaten kleiner dicarbonsäuren in kombination mit ppi |
GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
US8352042B2 (en) * | 2006-11-28 | 2013-01-08 | The Alfred E. Mann Foundation For Scientific Research | Remote controls and ambulatory medical systems including the same |
US20110174855A1 (en) * | 2006-11-29 | 2011-07-21 | Yakima Products, Inc. | Vehicle top carriers |
CN101190208B (zh) * | 2006-11-30 | 2011-11-02 | 石药集团中奇制药技术(石家庄)有限公司 | 一种含有盐酸度洛西汀的药物制剂及其制备方法 |
SI2124884T1 (sl) | 2006-12-22 | 2019-09-30 | Ironwood Pharmaceuticals, Inc. | Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
JP5629581B2 (ja) | 2007-10-12 | 2014-11-19 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | 食物の摂取から独立した消化器疾患の治療方法 |
AU2009215514B9 (en) | 2008-02-20 | 2014-01-30 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
TWI519322B (zh) * | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
AU2009290712A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | Method for delivering a pharmaceutical composition to patient in need thereof |
WO2010096814A1 (en) * | 2009-02-23 | 2010-08-26 | Eurand, Inc. | Controlled-release compositions comprising a proton pump inhibitor |
CN101822671A (zh) * | 2009-03-06 | 2010-09-08 | 信谊药厂 | 雷贝拉唑组合物及其制备方法 |
JP2012531430A (ja) * | 2009-06-25 | 2012-12-10 | ポーゼン インコーポレイテッド | アスピリン療法を必要とする患者を治療するための方法 |
AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
CN101991543A (zh) * | 2009-08-10 | 2011-03-30 | 杭州赛利药物研究所有限公司 | 一种奥美拉唑肠溶干混悬剂及其制备方法 |
JP2011037787A (ja) * | 2009-08-13 | 2011-02-24 | Kyorin Pharmaceutical Co Ltd | 塩基性薬物のpHに依存しない安定放出組成物 |
EP2319504A1 (de) | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Feste pharmazeutische Dosierform |
US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
US20130202688A1 (en) | 2010-05-04 | 2013-08-08 | Sunilendu Bhushan Roy | Delayed release oral disintegrating pharmaceutical compositions of lansoprazole |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
MX2014007239A (es) | 2011-12-16 | 2014-08-08 | Atopix Therapeutics Ltd | Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica. |
CA2860231A1 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
CA2867891C (en) | 2012-03-19 | 2021-09-14 | Buck Institute For Research On Aging | App specific bace inhibitors (asbis) and uses thereof |
WO2013141827A1 (en) | 2012-03-21 | 2013-09-26 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Enteric coated solid pharmaceutical compositions for proton pump inhibitors |
EP2882304A1 (de) | 2012-08-07 | 2015-06-17 | Buck Institute For Research On Aging | Mehrkomponentige formulierung zur verbesserung der neurologischen funktion |
US9623047B2 (en) | 2012-12-27 | 2017-04-18 | Photo Finish Supplements, Llc | Composition and method for improving gastrointestinal health of equine |
WO2014113377A1 (en) | 2013-01-15 | 2014-07-24 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
ES2769578T3 (es) | 2013-02-12 | 2020-06-26 | Buck Inst Res Aging | Hidantoínas que modulan el procesamiento de APP mediado por BACE |
WO2015102829A1 (en) | 2013-12-30 | 2015-07-09 | Avery Dennison Corporation | Films for printing |
EP2933002A1 (de) | 2014-04-11 | 2015-10-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmazeutische kombinationen von dabigatran und protonenpumpeninhibitoren |
WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
WO2016126625A1 (en) | 2015-02-03 | 2016-08-11 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
EP3288556A4 (de) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Oral zerfallende zusammensetzungen |
CN108601746A (zh) | 2016-01-08 | 2018-09-28 | 加利福尼亚大学董事会 | 用于运载物递送的具有脂质双层包衣的中孔二氧化硅纳米颗粒 |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
WO2017197177A1 (en) | 2016-05-12 | 2017-11-16 | Buck Institute For Research On Aging | Compounds to promote normal processing of app |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
JP6981088B2 (ja) * | 2017-01-27 | 2021-12-15 | ニプロ株式会社 | 経口固形製剤 |
AU2018284335A1 (en) | 2017-06-12 | 2020-01-30 | Glytech Llc. | Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists |
CA3104810A1 (en) | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | Enhancing gaba's ability to modulate immune responses |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
KR102643707B1 (ko) | 2019-01-22 | 2024-03-04 | 에오비안 파마슈티컬스, 인크. | Mtorc 조절제 및 이의 용도 |
CN114569579B (zh) | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
CN112516100A (zh) * | 2020-12-31 | 2021-03-19 | 珠海润都制药股份有限公司 | 一种艾司奥美拉唑镁肠溶片及其制备方法 |
ES2924573B2 (es) * | 2021-03-18 | 2024-04-24 | Aora Health S L | Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal |
CN115715808A (zh) | 2021-08-26 | 2023-02-28 | 丽珠医药集团股份有限公司 | 用于干混悬剂的干混悬颗粒及其制备方法和用途 |
WO2023166488A1 (en) | 2022-03-04 | 2023-09-07 | Revagenix, Inc. | Broad spectrum aminoglycosides and uses thereof |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2540979A (en) * | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
GB760403A (en) * | 1952-10-16 | 1956-10-31 | Abbott Lab | Improvements in or relating to enteric coatings |
GB862376A (en) * | 1957-10-10 | 1961-03-08 | Pfizer & Co C | Sustained release pharmaceutical tablet |
US3131123A (en) * | 1959-03-13 | 1964-04-28 | Lab Francais De Therapeutique | Enteric tablets and manufacture thereof |
GB1190387A (en) * | 1966-05-24 | 1970-05-06 | Green Cross Corp | Enteric Coated Medicaments |
ZA743391B (en) * | 1974-05-28 | 1975-08-27 | A Warren | Therapeutic products |
JPS5157813A (en) * | 1974-11-14 | 1976-05-20 | Sankyo Co | Ll dooba mataha sonojudotaiseizaino seiho |
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS5867616A (ja) * | 1981-10-15 | 1983-04-22 | Tanabe Seiyaku Co Ltd | 腸溶性マイクロカプセル |
US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
DE3233764A1 (de) * | 1982-09-11 | 1984-03-15 | R.P. Scherer GmbH, 6930 Eberbach | Verfahren zur herstellung oraler dosierungseinheiten |
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
JPS6019715A (ja) * | 1983-07-12 | 1985-01-31 | Nisshin Flour Milling Co Ltd | 安定なイソカルボスチリル製剤 |
AU571312B2 (en) * | 1984-02-10 | 1988-04-14 | Nycomed Danmark A/S | Diffusion coated multiple-units dosage form |
SE8404065D0 (sv) * | 1984-08-10 | 1984-08-10 | Haessle Ab | Novel biologically active compounds |
US4685918A (en) * | 1985-02-01 | 1987-08-11 | Merck & Co., Inc. | Lipid osmotic pump |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
JPS62277322A (ja) * | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
-
1986
- 1986-04-30 GB GB08610573A patent/GB2189699A/en not_active Withdrawn
-
1987
- 1987-04-01 ZA ZA872379A patent/ZA872379B/xx unknown
- 1987-04-15 YU YU68087A patent/YU46421B/sh unknown
- 1987-04-16 DE DE3751851T patent/DE3751851T2/de not_active Expired - Lifetime
- 1987-04-16 DE DE198787850126T patent/DE244380T1/de active Pending
- 1987-04-16 ES ES87850126T patent/ES2010648T3/es not_active Expired - Lifetime
- 1987-04-16 ES ES92107178T patent/ES2089277T3/es not_active Expired - Lifetime
- 1987-04-16 AT AT93201612T patent/ATE186639T1/de not_active IP Right Cessation
- 1987-04-16 EP EP93201612A patent/EP0565210B1/de not_active Expired - Lifetime
- 1987-04-16 AT AT92107178T patent/ATE139692T1/de not_active IP Right Cessation
- 1987-04-16 DE DE8787850126T patent/DE3783386T2/de not_active Expired - Lifetime
- 1987-04-16 CY CY186087A patent/CY1860A/xx unknown
- 1987-04-16 EP EP87850126A patent/EP0244380B1/de not_active Expired - Lifetime
- 1987-04-16 EP EP92107178A patent/EP0502556B1/de not_active Expired - Lifetime
- 1987-04-20 US US07/040,490 patent/US4853230A/en not_active Expired - Lifetime
- 1987-04-23 AU AU71922/87A patent/AU603568B2/en not_active Expired
- 1987-04-25 MY MYPI87000542A patent/MY102675A/en unknown
- 1987-04-27 PH PH35182A patent/PH24440A/en unknown
- 1987-04-27 EG EG244/87A patent/EG18517A/xx active
- 1987-04-27 NZ NZ220097A patent/NZ220097A/en unknown
- 1987-04-28 DZ DZ870070A patent/DZ1078A1/fr active
- 1987-04-28 IS IS3222A patent/IS1918B/is unknown
- 1987-04-28 DK DK215987A patent/DK169987B1/da not_active IP Right Cessation
- 1987-04-28 IE IE110687A patent/IE61837B1/en not_active IP Right Cessation
- 1987-04-29 SU SU874202437A patent/SU1709894A3/ru active
- 1987-04-29 CA CA000535903A patent/CA1302891C/en not_active Expired - Lifetime
- 1987-04-29 DD DD30225487A patent/DD260222B5/de active IP Right Maintenance
- 1987-04-29 HU HU871947A patent/HU198385B/hu unknown
- 1987-04-29 NO NO871791A patent/NO174952C/no unknown
- 1987-04-29 PT PT84786A patent/PT84786B/pt unknown
- 1987-04-29 PL PL1987265417A patent/PL265417A1/xx unknown
- 1987-04-29 FI FI871914A patent/FI91708C/fi not_active IP Right Cessation
- 1987-04-29 KR KR1019870004133A patent/KR950004886B1/ko not_active IP Right Cessation
- 1987-04-30 CN CN87103285A patent/CN1025151C/zh not_active Expired - Lifetime
- 1987-04-30 JP JP62108763A patent/JPH0667837B2/ja not_active Expired - Lifetime
- 1987-04-30 AR AR87307448A patent/AR243377A1/es active
- 1987-04-30 CS CS873073A patent/CS268535B2/cs not_active IP Right Cessation
-
1990
- 1990-03-14 GR GR89300156T patent/GR890300156T1/el unknown
-
1993
- 1993-03-23 GR GR930400635T patent/GR3007448T3/el unknown
-
1995
- 1995-06-29 HK HK104095A patent/HK104095A/xx not_active IP Right Cessation
-
1997
- 1997-05-01 HK HK55497A patent/HK55497A/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE244380T1 (de) | Arzneiformulierungen saeurelabiler substanzen zur oralen verwendung. | |
DE247983T1 (de) | Arzneizubereitung zur oralen anwendung. | |
DE3874360T2 (de) | Kugelfoermige granula mit kern sowie deren herstellung. | |
DE60020967T2 (de) | Kristalle von lansoprazole | |
DE69628444T2 (de) | Säurelabile omeprazol enthaltende pharmazeutische zusammensetzung und verfahren zu dessen herstellung | |
EP0589981B1 (de) | Pantoprazol enthaltende orale darreichungsformen | |
DE60100186T2 (de) | Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung | |
EP1485094B2 (de) | Oral zu applizierende darreichungsform für 3- [(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester oder dessen salze | |
DE69720774T2 (de) | S-omeprazol in festform | |
DE723436T1 (de) | Aus mehreren einzeleinheiten zusammengesetzte dosierungsform in tablettenform (i) | |
SK166096A3 (en) | New oral pharmaceutical formulation containing magnesium salt of omeprazole | |
DE69932576T2 (de) | Enterisch überzogene Formulierung eines Benzimidazolderivates und Verfahren zu deren Herstellung | |
DE69918854T2 (de) | Verbesserter chemischer prozess und eine pharmazeutische zubereitung | |
WO1992004898A1 (de) | Verwendung von pyridylmethylsulfinyl-1h-benzimidazol derivaten zur behandlung durch helicobacter verursachten erkrankungen | |
EP1235555B1 (de) | Stabile galenische zubereitungen umfassend ein benzimidazol und verfahren zu ihrer herstellung | |
DE3586420T2 (de) | Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose. | |
JP2798588B2 (ja) | 抗菌剤 | |
EP0482043B1 (de) | Monohydrochlorid und Monomethansulfonat von Amonafide. | |
DD260222A5 (de) | Verfahren zur Herstellung eines oralen pharmazeutischen Präparates, daseine säureunbeständige Verbindung enthält | |
DE10234617B4 (de) | Neues Salz von (S)-Pantoprazol | |
EP1726305A1 (de) | Zinksalz des Omeprazols und dessen Enantiomere | |
DE2259491A1 (de) | Neue alpha-aminopropionylphenthiazinderivate und verfahren zu ihrer herstellung | |
EP0306938A3 (de) | Festuclavin- und Pyroclavin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
SI8710680B (sl) | Farmacevtski pripravki kislinsko labilnih substanc za oralno uporabo | |
JPS6191123A (ja) | 新規抗潰瘍剤 |